Kala Bio Announces CMO Departure, New Directors
Ticker: KALA · Form: 8-K · Filed: Sep 25, 2024 · CIK: 1479419
Sentiment: neutral
Topics: management-change, board-election, personnel
TL;DR
Kala Bio's CMO is out, new board members in. Big changes at the top.
AI Summary
Kala Bio, Inc. announced on September 23, 2024, the departure of its Chief Medical Officer, Dr. Marcus Magnus, effective September 20, 2024. The company also appointed Dr. Michael Heffernan as interim Chief Medical Officer. Additionally, the board elected two new directors, Ms. Sarah Kelly and Mr. David Epstein, to fill existing vacancies.
Why It Matters
This filing indicates a significant leadership change in the medical department and an expansion of the board, which could impact the company's strategic direction and drug development pipeline.
Risk Assessment
Risk Level: medium — Leadership changes and board restructuring can signal internal challenges or strategic shifts that may affect future performance.
Key Players & Entities
- KALA BIO, Inc. (company) — Registrant
- Dr. Marcus Magnus (person) — Departing Chief Medical Officer
- Dr. Michael Heffernan (person) — Interim Chief Medical Officer
- Ms. Sarah Kelly (person) — Newly Elected Director
- Mr. David Epstein (person) — Newly Elected Director
- September 23, 2024 (date) — Report Date
- September 20, 2024 (date) — Effective Date of CMO Departure
FAQ
Who has departed from Kala Bio, Inc. and in what capacity?
Dr. Marcus Magnus, the Chief Medical Officer, has departed from Kala Bio, Inc.
When was Dr. Marcus Magnus's departure effective?
Dr. Marcus Magnus's departure was effective September 20, 2024.
Who has been appointed as the interim Chief Medical Officer?
Dr. Michael Heffernan has been appointed as the interim Chief Medical Officer.
Who are the new directors elected to the board?
Ms. Sarah Kelly and Mr. David Epstein have been elected as new directors.
What is the exact date of this Form 8-K filing?
The Form 8-K filing is dated September 25, 2024, and reports events as of September 23, 2024.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-09-25 16:06:26
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share KALA The Nasdaq C
Filing Documents
- tm2424692d1_8k.htm (8-K) — 22KB
- 0001104659-24-102775.txt ( ) — 188KB
- kala-20240923.xsd (EX-101.SCH) — 3KB
- kala-20240923_lab.xml (EX-101.LAB) — 33KB
- kala-20240923_pre.xml (EX-101.PRE) — 22KB
- tm2424692d1_8k_htm.xml (XML) — 3KB
02. Departure of Directors or Certain Officers; Election
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 23, 2024, Mark S. Blumenkranz, M.D. notified KALA BIO, Inc. (the "Company") of his decision to resign as a member of the Board of Directors of the Company, effective immediately. With the resignation, Dr. Blumenkranz also resigned as a member of the Company's Audit Committee and Nominating and Corporate Governance Committee. Dr. Blumenkranz informed the Company that his resignation was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALA BIO, INC. Date: September 25, 2024 By: /s/ Mary Reumuth Mary Reumuth Chief Financial Officer and Corporate Secretary